The Portuguese government authorised an expenditure of 32.7 million euros ($35.9 million) for the purchase of medicines against Covid-19 in 2022, according to a government decree published.
The resolution of the Council of Ministers on Monday said the expenditure is necessary "because of the evolution of the pandemic situation," and aims to ensure the Portuguese people have access to "therapeutic options for the disease caused by the SARS-CoV-2 virus".
Signed by Portuguese Prime Minister Antonio Costa, the order authorises the acquisition of the antiviral drug Remdesivir, as well as funding for the storage and acquisition of vaccines against Covid-19, Xinhua news agency reported.
The Portuguese government said the expenditure is justified to "put an end to the pandemic" and provide "therapeutic alternatives to treat infected people", such as "monoclonal antibodies," "oral antivirals," and "immunomodulators".
Access to these medicines can only be granted through a centralised procurement procedure within the framework of the Strategy for Covid-19 Therapeutics program, whose management is the responsibility of the European Commission. (1 euro $1.10)
--IANS
int/khz/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)